

Healthcare Common Procedure Coding System Quarterly Update

Effective July 1, 2023

The Centers for Medicare and Medicaid Services (CMS) publishes updates to the Healthcare Procedure Coding System (HCPCS) on a quarterly basis. Public use files may be downloaded from the "[HCPCS Quarterly Update](#)" page. Be sure to update any systems accordingly.

Advanced Diagnostic Laboratory Tests (ADLT)

0295U Oncology (breast ductal carcinoma in situ) protein expression profiling by immunohistochemistry of 7 proteins (cox2, foxa1, her2, ki-67, p16, pr, siah2) with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reported as a recurrence risk

Proprietary Lab Analyses (PLA)

NEW codes

0387U Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression

0388U Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection

0391U Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splicesite variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score

0395U Oncology (lung), multi-omics (microbial DNA by shotgun next generation sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease

0397 (Oncology (non-small cell lung cancer), cell-free DNA from plasma, targeted sequence analysis of at least 109 genes, including sequence variants, substitutions, insertions, deletions, select rearrangements, and copy number variations

Drugs

NEW Codes

J9029 Injection, nadofaragene firadenovec-vncg, per therapeutic dose

J9056 Injeciton, bendamustine hydrochloride (vivimusta), 1 mg

J9058 Injection, bendamustine hydrochloride (apotex), 1 mg

J9059 Injection, bendamustine hydrochloride (baxter), 1 mg

J9063 Injection, mirvetuximab soravtansine-gynx, 1 mg

J9259 Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to j9264, 1 mg

J9321 Injection, pemetrexed (sandoz) not therapeutically equivalent to j9305, 10 mg

J9322 Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg

J9323 Injection, pemetrexed (hospira) not therapeutically equivalent to j9305, 10 mg

J9347 Injection, tremelimumab-actl, 1 mg

J9350 Injection, mosunetuzumab-axgb, 1 mg

J9380 Injection, teclistamab-cqyv, 0.5mg

J9381 Injection, teplizumab-mzwv, 5 mcg

DISCONTINUED Codes

C9146 Injection, mirvetuximab soravtansive-gynx, 1 mg

C9147 Injection, tremelimumab-actl, 1 mg

C9148 Injection, teclistamab-cqyv, 0.5 mg

C9149 Injection, teplizumab-mzwv, 5 mcg

Category III Codes

0794T Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately